Interaction Between Inflammaging and Common Cardiovascular Diseases: Current Knowledge and Treatment

Inflammation plays a key role in the pathogenesis of major cardiovascular diseases such as hypertension, atherosclerosis, and heart failure. Chronic immune activation leads to endothelial dysfunction, contributing to increased oxidative stress, and abnormal neurohormonal responses. In patients with hypertension, vascular constriction, increased stiffness, and vascular wall remodeling occur, and activation of the renin–angiotensin–aldosterone system (RAAS) intensifies the inflammatory response through the action of angiotensin II, which stimulates the production of reactive oxygen species and inflammatory mediators. In patients with atherosclerosis, oxidized LDL activates endothelial cells and attracts monocytes, which migrate to the vessel wall and differentiate into macrophages. As the disease progresses, further activation of the immune system occurs, along with the secretion of proinflammatory cytokines (including IL‐1β, IL‐6, and TNF‐α), and proliferation of smooth muscle cells, leading to the formation of atherosclerotic plaque. In the case of heart failure, the role of the NLRP3 inflammasome is crucial, as it activates IL‐1β and intensifies the inflammatory response in the myocardium, contributing to the progression of heart failure. Progress in understanding immunological mechanisms has led to the development of modern therapeutic strategies aimed at addressing the inflammatory process. In addition to classic pleiotropic drugs such as statins and ACE inhibitors, targeted therapies are gaining increasing importance, including interleukin‐1 inhibitors (e.g., canakinumab), colchicine, and IL‐6 inhibitors, which have been shown to reduce cardiovascular risk regardless of lipid levels. Integration of modern anti‐inflammatory therapies with standard treatment opens up new possibilities for improving patient prognosis and personalizing therapy.

Authors

Institutions

Publication Details

Journal
Comprehensive physiology
Published
2026-11-18
DOI
https://doi.org/10.1002/cph4.70288
Primary Topic
Atherosclerosis and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Interaction Between Inflammaging and Common Cardiovascular Diseases: Current Knowledge and Treatment

Jarosław Hiczkiewicz, Łukasz Walas, Katarzyna Koleśnik, Agnieszka Zembroń-Łacny et al.
Comprehensive physiology
Atherosclerosis and Cardiovascular Diseases
article

Interaction Between Inflammaging and Common Cardiovascular Diseases: Current Knowledge and Treatment

Jarosław Hiczkiewicz, Łukasz Walas, Katarzyna Koleśnik, Agnieszka Zembroń-Łacny, Anna Tylutka, Paweł Muszyński
article en

Abstract

Inflammation plays a key role in the pathogenesis of major cardiovascular diseases such as hypertension, atherosclerosis, and heart failure. Chronic immune activation leads to endothelial dysfunction, contributing to increased oxidative stress, and abnormal neurohormonal responses. In patients with hypertension, vascular constriction, increased stiffness, and vascular wall remodeling occur, and activation of the renin–angiotensin–aldosterone system (RAAS) intensifies the inflammatory response through the action of angiotensin II, which stimulates the production of reactive oxygen species and inflammatory mediators. In patients with atherosclerosis, oxidized LDL activates endothelial cells and attracts monocytes, which migrate to the vessel wall and differentiate into macrophages. As the disease progresses, further activation of the immune system occurs, along with the secretion of proinflammatory cytokines (including IL‐1β, IL‐6, and TNF‐α), and proliferation of smooth muscle cells, leading to the formation of atherosclerotic plaque. In the case of heart failure, the role of the NLRP3 inflammasome is crucial, as it activates IL‐1β and intensifies the inflammatory response in the myocardium, contributing to the progression of heart failure. Progress in understanding immunological mechanisms has led to the development of modern therapeutic strategies aimed at addressing the inflammatory process. In addition to classic pleiotropic drugs such as statins and ACE inhibitors, targeted therapies are gaining increasing importance, including interleukin‐1 inhibitors (e.g., canakinumab), colchicine, and IL‐6 inhibitors, which have been shown to reduce cardiovascular risk regardless of lipid levels. Integration of modern anti‐inflammatory therapies with standard treatment opens up new possibilities for improving patient prognosis and personalizing therapy.

Comprehensive physiologyVol. 16(6)
Medical University of Białystok (PL), Institute of Dendrology (PL), University of Zielona Góra (PL), Polish Academy of Sciences (PL)
Atherosclerosis and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon